223519-08-2

Basic information

• Product Name: 3-BROMO-4-METHYL-5-NITROBENZOIC ACID METHYL ESTER
• Synonyms: 3-BROMO-4-METHYL-5-NITROBENZOIC ACID METHYL ESTER;3-BROMO-4-MEHTYL-5-NITROBENZOIC ACID METHYL ESTER;3-BROMO-4-METHYL-5-NITROBENZOIC ACID METHYL EST
• CAS NO: 223519-08-2
• Molecular Formula: C₉H₈BrNO₄
• Molecular Weight: 274.07
• Mol File: 223519-08-2.mol

Chemical Properties

• Boiling Point: 337.7°Cat760mmHg
• Flash Point: 158°C
• Appearance: /
• Density: 1.596g/cm³
• Vapor Pressure: 0.000103mmHg at 25°C
• Refractive Index: 1.579
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3-BROMO-4-METHYL-5-NITROBENZOIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-4-METHYL-5-NITROBENZOIC ACID METHYL ESTER(223519-08-2)
• EPA Substance Registry System: 3-BROMO-4-METHYL-5-NITROBENZOIC ACID METHYL ESTER(223519-08-2)

Safety Data

• Hazardous Substances Data: 223519-08-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-BROMO-4-METHYL-5-NITROBENZOIC ACID METHYL ESTER is used as a building block in the synthesis of pharmaceuticals and other organic compounds. Its unique structure allows it to be a key intermediate in the creation of complex organic molecules, contributing to the development of new drugs and chemical products.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 3-BROMO-4-METHYL-5-NITROBENZOIC ACID METHYL ESTER is utilized as a reagent in chemical reactions that facilitate the discovery and production of new medications. Its properties make it suitable for use in the synthesis of potential drug candidates, aiding researchers in their quest to find novel therapeutic agents.
Used in Analytical Chemistry and Spectroscopic Techniques:
3-BROMO-4-METHYL-5-NITROBENZOIC ACID METHYL ESTER also serves as a reference standard in analytical chemistry. It is employed to calibrate instruments and validate analytical methods, ensuring the accuracy and reliability of experimental results. Its use in spectroscopic techniques helps in the identification and characterization of compounds, playing a crucial role in quality control and research processes.

InChI:InChI=1/C9H8BrNO4/c1-5-7(10)3-6(9(12)15-2)4-8(5)11(13)14/h3-4H,1-2H3

Upstream product

• 96-98-0 4-methyl-3-nitrobenzoic acid 
• 67-56-1 methanol 
• 34545-20-5 3-bromo-4-methyl-5-nitro-benzoic acid 
• 882679-96-1 methyl 4-bromo-1H-indole-6-carboxylate 

Downstream Products

• 1285532-20-8 C₂₁H₂₅N₅O 
• 1285531-68-1 1-(4-(6-(N-(2-(piperidin-1-yl)ethyl)aminocarbonyl)-1H-indazol-4-yl)phenyl)-3-(3-(trifluoromethoxy)phenyl)urea 
• 885518-47-8 methyl 4-bromo-1H-indazole-6-carboxylate 
• 885523-43-3 4-bromo-1H-indazole-6-carboxylic acid 
• 1638772-21-0 methyl 4-bromo-2-methyl-2H-indazole-6-carboxylate 
• 1638759-79-1 methyl 4-bromo-1-methyl-1H-indazole-6-carboxylate 
• 882679-96-1 methyl 4-bromo-1H-indole-6-carboxylate 
• 885518-53-6 4-bromo-1H-indazol-6-amine 
• 1527007-77-7 methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole-6-carboxylate 
• 170487-40-8 1H-indazole-6-carboxylic acid methyl ester 

Relevant articles and documents

SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE

The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof, or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof, and methods and compositions for treating or ameliorating abnormal cell pr

CARBOXY SUBSTITUTED (HETERO) AROMATIC RING DERIVATIVES AND PREPARATION METHOD AND USES THEREOF

Carboxy-substituted (hetero)aryl derivatives, pharmaceutical compositions comprising these compounds, and methods of preparing such compounds and compositions are provided. The compounds or compositions are useful in inhibiting xanthine oxidase and urate anion transporter 1, and also can be used in the treatment or prevention of diseases associated with high blood uric acid level in mammals, especially humans.

Synthesis of substituted 4-(1H-indol-6-yl)-1H-indazoles as potential PDK1 inhibitors

The development of a preparative route to a series of novel 4-(1H-indol-6-yl)-1H-indazole compounds as potential PDK1 inhibitors is described. The synthetic strategy centres on the late-stage Suzuki cross-coupling of N-unprotected indazole and indole frag

COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly di